Association between serum resistin level and diabetic retinopathy in obese patients with type 2 diabetes mellitus
N.V. Malachkova1, Cand Sc (Med), M.L. Kyryliuk2, Dr Sc (Med), Prof., I.V. Komarovska1, Post-grad Student
1Pirogov National Medical University, Vinnytsia, Ukraine
2Department of Neuroendocrinology, Ukrainian Research Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of Ministry of Public Health of Ukraine, Kyiv
Background: Diabetic retinopathy (DR) is a leading cause of blindness in developed countries. Factors like inadequate glycemic control, hypertonia, blood lipid disorder, and renal disease, are known to negatively affect vision, and may cause loss of sight. Some studies demonstrate that there are additional contributors to the development of DR.
Purpose: To investigate the relationship between serum resistin levels and diabetic retinopathy in obese patients with type 2 diabetes mellitus (T2DM).
Materials and Methods: Seventy-nine patients (mean age, 59.57 ± 4.01 years; mean duration of diabetes, 9.97±2.46 years; mean HbA1c, 10.31±1.89%) with T2DM and body mass index (BMI) > 24.99 kg/m2 underwent examination. Serum resistin levels were measured by ELISA. Analysis of variance was used for data analysis.
Results: The serum resistin levels were 4.84 ± 0.41 ng/mL (95% CI, 4.26 to 5.41) in the non-diabetic control group and gradually increased with the severity of DR to the maximum of 6.19 ± 0.65 ng/mL (95% CI, 5.27 to 7.11) in moderate to severe non-proliferative DR (P = 0.18).
Conclusion: Patients with proliferative DR and any risk factors had moderately increased mean serum resistin levels, with the highest values being noted in duration of diabetes of more than 10 years.
Key-words: type 2 diabetes mellitus, obesity, diabetic retinopathy, resistin
- Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab. 2004;6(3):163–70.
- Osawa H, Ochi M, Kato K, et al. Serum resistin is associated with the severity of microangiopathies in type 2 diabetes. Biochem Biophys Res Commun. 2007;355(2):342–6.
- Osawa H, Ochi M, Tabara Y, et al. Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol (Oxf). 2008 Jul;69(1):74-80. Epub 2008 Jul 1
- Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation (WHO/NMH/CHP/CPM/11.1). World Health Organization; 2011.
- Steppan C, Lazar M. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 2002;13:18–23.
- Bełtowski J. Adiponectin and resistin - new hormones of white adipose tissue. Med Sci Monit. 2003 Feb;9(2):RA55-61.
- Wolf G. Insulin resistance and obesity: resistin, a hormone secreted by adipose tissue. Nutr Rev. 2004;62(10):389–94.
- Steppan C, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409 (6818):307–12.
- Farvid MS, Ng TW, Chan DC, et al. Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes Metab. 2005;7(4): 406–13.
- Schäffler A, Büchler C, Müller-Ladner U, et al. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Horm Metab Res. 2004;36(10):702-7.
- Naglaa A, Taher A, Amr, El-deen IM. Correlation of serum resistin level with insulin resistance and severity of retinopathy in type 2 diabetes mellitus. Journal of Saudi Chemical Society. 2016;20(3):272–7.
- Silha JV, Krsek M, Skrha JV, et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003;149:331–5.
- Smith SR, Bai F, Charbonneau C, et al. Promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes. 2003;52:1611–8.